Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:711-712 (20 March), doi:10.1136/bmj.328.7441.711-c
| The first 150 words of the full text of this article appear below. |
EDITORThe use of antidepressants in children is increasing, although the evidence for the effectiveness and safety of pharmacological treatment of depressive disorder in children and adolescents is scant1 and widely debated2particularly for selective serotonin reuptake inhibitors (SSRIs).3 4
We used the ARNO database (http://sanita.cineca.it/public/arno/arnoeng.htm) to analyse drug prescriptions written during 2002 to 568 770 Italian patients under 18. A total of 1600 young people (2.8 per 1000) received at least one antidepressant, 1200 of them an SSRI and 297 a tricyclic antidepressant. Two thirds of prescriptions (8284/11 369) were for adolescents (age 14-17), mostly girls (4583/5872; rate 10.6 per 1000 v 5.9 per 1000 for boys).
These prescribing rates are lower than those reported for the United States (1-2%) and the Netherlands (4.4 per 1000), but nevertheless about 28 000 youths are exposed to treatment with antidepressants, 21 000 of them receiving SSRIs. We found a
Antonio Clavenna, senior research fellow
clavenna@marionegri.it
Maurizio Bonati, head
Laboratory for Mother and Child Health, Mario Negri Institute for Pharmacological Research, 20157 Milan, Italy
Elisa Rossi, statistician, Marisa De Rosa, senior researcher
Interuniversity Consortium, Bologna, Italy